Company intelligence / Profile preview
LeonaBio
Bothell, Washington, United Statesleonabio.com ↗
- Ownership
- Public · LONA
- Employees
- ~75
- Development stage
- Phase 3
01
Overview
LeonaBio is currently advancing its lead asset, lasofoxifene, in the pivotal Phase 3 ELAINE-3 clinical trial for metastatic breast cancer, with data expected in mid-2027. The company's second lead candidate, ATH-1105, recently completed a Phase 1 first-in-human trial in 80 healthy volunteers, demonstrating safety and tolerability; a Phase 2 trial in patients with ALS is planned for initiation in early 2026.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Sermonix Pharmaceuticals
Beyond the preview
Go deeper on LeonaBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LeonaBio.